Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.40 |
| ▸ | CDK2 | P24941 | 9/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | PDE8A | O60658 | 3/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416142 | 0.82 | P2RX7 (0.37) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL29426182 | 0.82 | CDK2 (0.56) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL539356 | 0.82 | CDK2 (0.56) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL27897027 | 0.79 | CDK2 (0.44) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL30148781 | 0.78 | CDK1 (0.41) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL1913380 | 0.78 | CDK1 (0.41) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL30331956 | 0.77 | ADORA2A (0.50) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL946328 | 0.77 | ADORA2A (0.50) | P2RX7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL3348188 | 0.75 | P2RX7 (0.48) | P2RX7LMNATP53PDE8ANPC1 | |
| SCHEMBL2848856 | 0.75 | CCNA2 (0.41) | P2RX7CCNA2CDK2CCNA1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118451077-A | Bicyclic therapeutic compounds and methods for treatment of cancer | 基因泰克公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-07-25 | — | — | US | disclosed |
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | P2RX7 2237/4885CCNA2 2259/4885CDK2 1472/4885 |
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | P2RX7 563/4885CCNA2 10/4885CDK2 1/4885 |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | P2RX7 2237/4885CCNA2 2259/4885CDK2 1472/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | P2RX7 563/4885CCNA2 10/4885CDK2 1/4885 |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | P2RX7 563/4885CCNA2 10/4885CDK2 1/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | P2RX7 2237/4885CCNA2 2259/4885CDK2 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.